Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists-Reference-Cited by-同舟云学术

Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists

Published:2022-04-13 Issue:5 Volume:17 Page:1143-1154
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Griffett Kristine¹,Hayes Matthew²,Bedia-Diaz Gonzalo³,Appourchaux Kevin³,Sanders Ryan²,Boeckman Michael P.³,Koelblen Thomas²,Zhang Jinsong⁴,Schulman Ira G.⁵,Elgendy Bahaa³^ORCID,Burris Thomas P.²^ORCID

Affiliation:

1. Department of Anatomy, Physiology and Pharmacology, Auburn University College of Veterinary Medicine, Auburn, Alabama 36849, United States

2. University of Florida Genetics Institute, Gainesville, Florida 32610, United States

3. Center for Clinical Pharmacology, Washington University School of Medicine and St. Louis College of Pharmacy, St. Louis, Missouri 63110, United States

4. Department of Pharmacology & Physiology, Saint Louis University School of Medicine, St. Louis, Missouri 63104, United States

5. Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 22903, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

American Heart Association

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.2c00057

Reference40 articles.